2023 World Conference on Lung Cancer (Posters)-P1.11. Utility of ctDNA Monitoring during Surveillance in Surgically Resected NSCLC Patients

P1.11. Utility of ctDNA Monitoring during Surveillance in Surgically Resected NSCLC Patients - PDF(Abstract)

Pdf Summary

A study was conducted to evaluate the use of monitoring circulating tumor DNA (ctDNA) during surveillance in patients with surgically resected non-small cell lung cancer (NSCLC). The study included 46 patients with stage II-III NSCLC who underwent surgical resection and were followed up for a median of 20 months. Plasma samples were collected pre- and post-surgery, and ctDNA was detected using patient-specific multiplex-PCR assays. <br /><br />The results showed that ctDNA was detected in 5 patients shortly after surgery, and all of them experienced radiographic recurrence within 11 months. The presence of ctDNA at this time point was associated with worse recurrence-free survival. Additionally, 5 more patients became ctDNA-positive during surveillance, and ctDNA detection at any time point was associated with shorter recurrence-free survival. CtDNA positivity preceded radiographic findings by a median of 2.8 months. On the other hand, patients who tested ctDNA-negative had a favorable outcome, with a negative predictive value of 83.3%.<br /><br />These findings suggest that ctDNA detection during post-surgery follow-up can potentially identify early-stage NSCLC patients at high risk of recurrence. The study highlights the potential utility of longitudinal ctDNA monitoring in guiding post-resection surveillance and treatment in NSCLC patients. However, further prospective studies are needed to assess the clinical usefulness of this approach.<br /><br />In summary, this study demonstrates the potential of ctDNA monitoring in predicting cancer recurrence and personalizing treatment in surgically resected NSCLC patients. By detecting ctDNA during post-surgery follow-up, early-stage NSCLC patients at high risk of recurrence can be identified, allowing for timely intervention.

Asset Subtitle

Shuta Ohara

Meta Tag

Speaker Shuta Ohara

Topic Tumor Biology: Translational Biology - Omics and New Technologies

Keywords

ctDNA

circulating tumor DNA

surveillance

non-small cell lung cancer

NSCLC

surgical resection

recurrence

monitoring

post-surgery follow-up

personalized treatment